Abstract
Objective To study the clinical value of serum SCC,CYFRA21-1,NSE and CEA for patients with nasopharyngeal carcinoma (NPC) and squamous cell carcinoma of head and neck (NHSCC). Methods From Aug 2004 to Sep 2007, the serum levels of SCC, CYFRA21-1, NSE and CEA were detected in 79 NPC and 51 HNSCC before and after radiotherapy. The clinical related factors were analyzed. Results Before treatment, the positive rates of serum SCC, CYFRA21-1, NSE and CEA for patients with NPC were 10.53 %, 46.75 %, 17.5 % and 2.04 %, respectively. The sensitivity of combined detection was 78.95 %. The positive rates for patients with HNSCC were 22 %, 19.75 %, 11.11% and 0, respectively. The sensitivity of combined detection was 36.17 %. The level of SCC was related to staging in HNSCC group. CYFRA21-1 was related to the rote of treatment response in NPC group. Conclusion The sensitivity of combined detection of tumor markers were significantly increased. CYFRA21-1 associated with NPC and SCC with HNSCC were noted in this study. Key words: Head and neck neoplasms; Nasopharyngeal neoplasms; Radiotherapy, computer-assisted; Tumor markers, biological
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
